JP5808408B2 - フタラジノンケトン誘導体、その製造法および医薬用途 - Google Patents
フタラジノンケトン誘導体、その製造法および医薬用途 Download PDFInfo
- Publication number
- JP5808408B2 JP5808408B2 JP2013523468A JP2013523468A JP5808408B2 JP 5808408 B2 JP5808408 B2 JP 5808408B2 JP 2013523468 A JP2013523468 A JP 2013523468A JP 2013523468 A JP2013523468 A JP 2013523468A JP 5808408 B2 JP5808408 B2 JP 5808408B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- pyrazine
- mmol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1C=Cc([o]cc2)c2C=C1 Chemical compound C*1C=Cc([o]cc2)c2C=C1 0.000 description 8
- PAXLJNGPFJEKQX-UHFFFAOYSA-N OC(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O Chemical compound OC(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O PAXLJNGPFJEKQX-UHFFFAOYSA-N 0.000 description 2
- YZBDXDPBLIQCJY-UHFFFAOYSA-N C1NCc2ccc[n]2C1 Chemical compound C1NCc2ccc[n]2C1 YZBDXDPBLIQCJY-UHFFFAOYSA-N 0.000 description 1
- UANMXKOQPAYQTK-SREVYHEPSA-N CC(C)(C=C)/C=C\c1c(C)[s]cn1 Chemical compound CC(C)(C=C)/C=C\c1c(C)[s]cn1 UANMXKOQPAYQTK-SREVYHEPSA-N 0.000 description 1
- HBYQLDXFOSICGN-UHFFFAOYSA-N CC(c1nnc(C2)[n]1CCN2C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O)(F)F Chemical compound CC(c1nnc(C2)[n]1CCN2C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)=O)(F)F HBYQLDXFOSICGN-UHFFFAOYSA-N 0.000 description 1
- CAXQEPUTRSXRFF-UHFFFAOYSA-N CC1(C)C=Cc([nH]nc2)c2C=C1 Chemical compound CC1(C)C=Cc([nH]nc2)c2C=C1 CAXQEPUTRSXRFF-UHFFFAOYSA-N 0.000 description 1
- MIKQYOLBQDHXOC-ATVHPVEESA-N CCC(C)C/C=N\C1=C(C)C=CC(C)(C)C=C1 Chemical compound CCC(C)C/C=N\C1=C(C)C=CC(C)(C)C=C1 MIKQYOLBQDHXOC-ATVHPVEESA-N 0.000 description 1
- UOBUHTDALANGAI-UHFFFAOYSA-N COC(c1c(CNCC2)[n]2c(C(F)(F)[I]=C)n1)=O Chemical compound COC(c1c(CNCC2)[n]2c(C(F)(F)[I]=C)n1)=O UOBUHTDALANGAI-UHFFFAOYSA-N 0.000 description 1
- FMTDZGCPYKWMPT-UHFFFAOYSA-N FC(c1nnc2[n]1CCNC2)(F)F Chemical compound FC(c1nnc2[n]1CCNC2)(F)F FMTDZGCPYKWMPT-UHFFFAOYSA-N 0.000 description 1
- WSRPPCUPGXRMRW-UHFFFAOYSA-N N=C(C(F)(F)F)N(CCN(C1)C(c2cc(CC(c3ccccc33)=NNC3=O)ccc2F)=O)C1=N Chemical compound N=C(C(F)(F)F)N(CCN(C1)C(c2cc(CC(c3ccccc33)=NNC3=O)ccc2F)=O)C1=N WSRPPCUPGXRMRW-UHFFFAOYSA-N 0.000 description 1
- DYWUYPWTHFULMZ-UHFFFAOYSA-N NC(c1c(CN(CC2)C(c(cc(CC(c3ccccc33)=NNC3=O)cc3)c3F)=O)[n]2c(C(F)(F)F)n1)=O Chemical compound NC(c1c(CN(CC2)C(c(cc(CC(c3ccccc33)=NNC3=O)cc3)c3F)=O)[n]2c(C(F)(F)F)n1)=O DYWUYPWTHFULMZ-UHFFFAOYSA-N 0.000 description 1
- ZWATXLDMXAWLLA-UHFFFAOYSA-N O=C(c1cc(CC(C2=C3C=CC=CC2)=NNC3=O)ccc1F)N1Cc2ccc[n]2CC1 Chemical compound O=C(c1cc(CC(C2=C3C=CC=CC2)=NNC3=O)ccc1F)N1Cc2ccc[n]2CC1 ZWATXLDMXAWLLA-UHFFFAOYSA-N 0.000 description 1
- JPYXQNYTOSHIAC-UHFFFAOYSA-N O=C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)N1Cc2ccc[n]2CC1 Chemical compound O=C(c1cc(CC(c2ccccc22)=NNC2=O)ccc1F)N1Cc2ccc[n]2CC1 JPYXQNYTOSHIAC-UHFFFAOYSA-N 0.000 description 1
- XUCMOPZFOKSXAA-UHFFFAOYSA-N O=C1OC2=CCCC=C2C=C1 Chemical compound O=C1OC2=CCCC=C2C=C1 XUCMOPZFOKSXAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010248307.5 | 2010-08-09 | ||
| CN2010102483075A CN102372716A (zh) | 2010-08-09 | 2010-08-09 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2011/001223 WO2012019427A1 (zh) | 2010-08-09 | 2011-07-26 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535491A JP2013535491A (ja) | 2013-09-12 |
| JP2013535491A5 JP2013535491A5 (enExample) | 2014-07-24 |
| JP5808408B2 true JP5808408B2 (ja) | 2015-11-10 |
Family
ID=45567315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523468A Active JP5808408B2 (ja) | 2010-08-09 | 2011-07-26 | フタラジノンケトン誘導体、その製造法および医薬用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9273052B2 (enExample) |
| EP (1) | EP2604610B1 (enExample) |
| JP (1) | JP5808408B2 (enExample) |
| KR (1) | KR101829940B1 (enExample) |
| CN (2) | CN102372716A (enExample) |
| AU (1) | AU2011288876B2 (enExample) |
| BR (1) | BR112013002220B1 (enExample) |
| CA (1) | CA2806324C (enExample) |
| ES (1) | ES2582315T3 (enExample) |
| HU (1) | HUE029275T2 (enExample) |
| PL (1) | PL2604610T3 (enExample) |
| PT (1) | PT2604610T (enExample) |
| RU (1) | RU2564527C2 (enExample) |
| UA (1) | UA111161C2 (enExample) |
| WO (1) | WO2012019427A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| MX2015006780A (es) * | 2012-12-31 | 2015-08-06 | Cadila Healthcare Ltd | Derivados de ftalazin-1-(2h)-ona sustituida. |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| CN106749261A (zh) * | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| CN107207504B (zh) * | 2015-12-16 | 2020-03-10 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| TWI771344B (zh) * | 2016-12-01 | 2022-07-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| EP3609897A1 (en) | 2017-04-12 | 2020-02-19 | H. Hoffnabb-La Roche Ag | A method for labeling of aldehyde containing target molecules |
| CA3073613A1 (en) * | 2017-08-24 | 2019-02-28 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of parp-1 inhibitor and preparation method therefor |
| MX2020005659A (es) * | 2017-12-06 | 2020-08-20 | Jiangsu Hengrui Medicine Co | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. |
| AU2019207072A1 (en) | 2018-01-09 | 2020-07-16 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing PARP inhibitor and intermediate thereof |
| WO2019145214A1 (en) | 2018-01-26 | 2019-08-01 | Recordati Industria Chimica E Farmaceutica S.P.A | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS |
| CA3129516A1 (en) * | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| CA3095367A1 (en) * | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020083187A1 (zh) * | 2018-10-22 | 2020-04-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 |
| WO2020098774A1 (zh) * | 2018-11-16 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种包含parp抑制剂的药物组合物 |
| TW202110448A (zh) * | 2019-05-28 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR102913343B1 (ko) | 2020-04-21 | 2026-01-15 | 아이디언스 주식회사 | 프탈라지논 화합물의 결정형 |
| WO2021214502A1 (en) | 2020-04-21 | 2021-10-28 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| CN111732594B (zh) * | 2020-08-18 | 2022-03-04 | 苏州富士莱医药股份有限公司 | 一种氟唑帕利的制备方法 |
| JP7777131B2 (ja) | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| KR20230080441A (ko) | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사 활성화 단백질의 이미다조피페라진 억제제 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| AU2022280845A1 (en) * | 2021-05-24 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| WO2023288002A1 (en) * | 2021-07-16 | 2023-01-19 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| JP2024528021A (ja) * | 2021-07-29 | 2024-07-26 | 上海齊魯制藥研究中心有限公司 | 新規なｐａｒｐ７阻害剤及びその使用 |
| CN115650988B (zh) * | 2022-10-27 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂的制备方法 |
| KR20250103773A (ko) * | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
| TW202502341A (zh) * | 2023-03-13 | 2025-01-16 | 大陸商江蘇豪森藥業集團有限公司 | 哌啶烯類化合物在製備治療癌症的藥物中的應用 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| KR100663147B1 (ko) * | 2002-02-19 | 2007-02-28 | 오노 야꾸힝 고교 가부시키가이샤 | 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제 |
| AR043443A1 (es) | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| KR20070057859A (ko) | 2004-08-26 | 2007-06-07 | 쿠도스 파마슈티칼스 리미티드 | 4-헤테로아릴메틸 치환된 프탈라지논 유도체 |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| MX347085B (es) * | 2006-12-28 | 2017-04-06 | Abbott Laboratories * | Inhibidores de la poli (adp-ribosa) polimerasa. |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| EP2190428A4 (en) | 2007-08-21 | 2012-02-29 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| JP2011509962A (ja) | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
-
2010
- 2010-08-09 CN CN2010102483075A patent/CN102372716A/zh active Pending
-
2011
- 2011-07-26 JP JP2013523468A patent/JP5808408B2/ja active Active
- 2011-07-26 HU HUE11815986A patent/HUE029275T2/en unknown
- 2011-07-26 RU RU2013106754/04A patent/RU2564527C2/ru active
- 2011-07-26 CN CN201180003990.9A patent/CN102686591B/zh active Active
- 2011-07-26 UA UAA201301524A patent/UA111161C2/uk unknown
- 2011-07-26 KR KR1020137003185A patent/KR101829940B1/ko active Active
- 2011-07-26 ES ES11815986.2T patent/ES2582315T3/es active Active
- 2011-07-26 PT PT118159862T patent/PT2604610T/pt unknown
- 2011-07-26 EP EP11815986.2A patent/EP2604610B1/en active Active
- 2011-07-26 BR BR112013002220-5A patent/BR112013002220B1/pt active IP Right Grant
- 2011-07-26 AU AU2011288876A patent/AU2011288876B2/en active Active
- 2011-07-26 CA CA2806324A patent/CA2806324C/en active Active
- 2011-07-26 US US13/811,957 patent/US9273052B2/en active Active
- 2011-07-26 WO PCT/CN2011/001223 patent/WO2012019427A1/zh not_active Ceased
- 2011-07-26 PL PL11815986.2T patent/PL2604610T3/pl unknown
-
2016
- 2016-02-05 US US15/016,986 patent/US9566277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UA111161C2 (uk) | 2016-04-11 |
| CN102686591B (zh) | 2014-03-19 |
| AU2011288876B2 (en) | 2014-08-21 |
| ES2582315T3 (es) | 2016-09-12 |
| EP2604610A4 (en) | 2013-12-25 |
| US20160151367A1 (en) | 2016-06-02 |
| JP2013535491A (ja) | 2013-09-12 |
| EP2604610B1 (en) | 2016-05-11 |
| AU2011288876A2 (en) | 2013-02-21 |
| KR20130110149A (ko) | 2013-10-08 |
| BR112013002220B1 (pt) | 2021-09-21 |
| RU2564527C2 (ru) | 2015-10-10 |
| PT2604610T (pt) | 2016-07-13 |
| EP2604610A1 (en) | 2013-06-19 |
| CN102686591A (zh) | 2012-09-19 |
| CN102372716A (zh) | 2012-03-14 |
| HUE029275T2 (en) | 2017-02-28 |
| US9273052B2 (en) | 2016-03-01 |
| CA2806324C (en) | 2019-02-19 |
| US20130131068A1 (en) | 2013-05-23 |
| WO2012019427A8 (zh) | 2012-05-10 |
| AU2011288876A1 (en) | 2013-01-31 |
| CA2806324A1 (en) | 2012-02-16 |
| PL2604610T3 (pl) | 2016-11-30 |
| KR101829940B1 (ko) | 2018-02-19 |
| BR112013002220A2 (pt) | 2016-05-24 |
| RU2013106754A (ru) | 2014-09-20 |
| HK1174030A1 (en) | 2013-05-31 |
| US9566277B2 (en) | 2017-02-14 |
| WO2012019427A1 (zh) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535491A (ja) | フタラジノンケトン誘導体、その製造法および医薬用途 | |
| ES2590682T3 (es) | Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos | |
| KR102599788B1 (ko) | 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클 | |
| CN102762549B (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| CN116514846A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
| JP2019522055A (ja) | Ｆｇｆｒ阻害剤として使用される複素環式化合物 | |
| CN106187915A (zh) | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 | |
| ES2927959T3 (es) | Compuestos de imidazol heterocíclicos, composiciones farmacéuticas de los mismos, método de preparación de los mismos y uso de los mismos | |
| CN115485281B (zh) | 一种fgfr及其突变抑制剂,其制备方法和应用 | |
| CN109761986B (zh) | 三并环类衍生物抑制剂、其制备方法和应用 | |
| CN118684666A (zh) | Kif18a抑制剂及其用途 | |
| CN104774188B (zh) | 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用 | |
| TWI548637B (zh) | 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用 | |
| HK40126810A (en) | Polycyclic poly(adp-ribose) polymerase selective inhibitor | |
| CN120829430A (zh) | 三稠环类衍生物抑制剂、其制备方法和应用 | |
| HK1174030B (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
| KR20230014505A (ko) | 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물 | |
| KR20260064598A (ko) | Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150326 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150625 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150902 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150908 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5808408 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |